4Q Revenues: $4.9 billion (-6%)
4Q Earnings: $498 million (-28%)
FY Revenues: $19.7 billion (-3%)
FY Earnings: $1.6 billion (-48%)
Comments: Specialty Medicines revenue was $2.1 billion in the quarter, down 6%, primarily due to lower sales of Copaxone and Azilect, which were partially offset by higher revenues of respiratory products. Specialty Medicines accounted for 44% of total revenues in the quarter. Generic Medicines revenue was $2.3 billion in the quarter, down 9%. R&D expenses were $395 million in the quarter, up 14%. Exchange rate fluctuations reduced revenues by $259 million in the quarter, and $1.3 billion for the year.